این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Research in Medical Sciences، جلد ۱۷، شماره ۹، صفحات ۰-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
چکیده انگلیسی مقاله Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 BACKGROUND: CA 15.3 is elevated in most patients with distant metastatic breast cancer who had prognostic information. The present study was performed to estimate predictive ability of CA 15.3 in assessment of symptomatic metastasis in patients with breast cancer. MATERIALS AND METHODS: During five years, 159 primary breast cancer patients were evaluated. A total of 2226 determination of serum CA 15.3 (14 per patient) were performed. We performed contemporary clinical examinations with CA 15.3 measurements at the time of diagnosis, end of chemotherapy, every three months in the first two years and every six months in the second two years of follow-up period. Imaging studies were performed if clinical or laboratory examinations (abnormal serum levels of CA 15.3) suspected symptomatic metastasis. Metastasis in participants was confirmed by imaging study in symptomatic patients. RESULTS: There was no significant increase in CA 15.3 tumor markers during chemotherapy ( P = 0.08). There was a significant relationship between CA 15.3 positive results and metastasis situation ( P = 0.00). Mean of maximum CA 15.3 level in metastatic patients (52.72 ± 27.09) was significantly higher than non-metastatic patients (27.58 ± 13.46; P = 0.00). CA 15.3 abnormality (OR, 1.07; 95% CI: 1.04-1.11; P value, 0.01) and abnormal lymph nodes remained as predictor of metastasis (OR: 1.16; 95% CI: 1.05-1.28; P value < 0.0001). CONCLUSION: CA 15.3 is one of the predicting factors for symptomatic metastasis.
کلیدواژه‌های انگلیسی مقاله Breast cancer, CA 15.3, metastasis, prediction
نویسندگان مقاله امیر بهرامی احمدی | amir bahrami ahmadi
borhan research institute, tehran, iran


فریبرز مکاریان | fariborz makarian
department of clinical oncology, isfahan university of medical sciences and health services, isfahan, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی اصفهان (Isfahan university of medical sciences)

محمد r مرتضوی زاده | mohammad r mortazavizadeh
department of clinical oncology, shahid sadoughi university of medical sciences and health services, yazd, iran


محمد f یزدی | mohammad f yazdi
department of clinical oncology, shahid sadoughi university of medical sciences and health services, yazd, iran


مهدی چمنی | mehdi chamani
shahid sadoughi university of medical sciences and health services, yazd, iran
نشانی اینترنتی http://jrms.mui.ac.ir/index.php/jrms/article/view/8620
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات